The integrated agency's pharmaceutical business now brings in half its billings.
Today's cancer therapies have an unlikely champion in their corner: the immune system. Scientists are training the natural disease defender to KO cancer for good—and pharma companies are drooling over the flashy premium prices and commercial success of marketed immunotherapies, which have ignited vigorous pipeline work. Rebecca Mayer Knutsen surveys the $32-billion US cancer segment
He didn't want to just invest in a winning horse—he wanted to help groom it
Test your knowledge in the inaugural edition of the MM&M Weekly News Quiz.
UnitedHealth looks for refunds when drugs don't work; the European Medicines Agency recommends Sanofi's and Regeneron's PCSK9 inhibitor, Praluent, for approval; Biogen's multiple-sclerosis drug, Tecfidera, reports lower-than-expected sales growth
Bristol-Myers Squibb reported a dip in US sales for the second quarter of 2015 but noted higher uptake for its immunoncology drug, Opdivo.
The deal is expected to complement the company's digital health platform.
Oncologists criticize cancer drug prices; Mylan exercises option to fend off Teva takeover; Valeant buys IBS diagnostic in latest acquisition
Taking a look back at what's happened—and what hasn't happened—on the healthcare communications policy front so far this summer
From the 21st Century Cures Act to Amarin's off-label suit, Marc Iskowitz asks seven experts what the confluence of policy developments means for pharma promotion
The focus on boosting physician referrals might appear contrary to the current obsession with patient-centric marketing.
A next-generation cardiovascular drug is expected to be approved this week, but concerns abound about who will take it—and how much it will cost.
Experimental Alzheimer's disease drugs produce mixed results; court rules in favor of Novartis in Zarxio case; Horizon Pharma increases its bid for Depomed
The modern healthcare landscape is complicated, and the terrain is even more gnarled for life sciences companies trying to bring new products to market.
The new campaign seeks to connect with millennial women.
Physicians criticize pricing of Orkambi, Vertex's new cystic-fibrosis drug; the EU approves Amgen's PCSK9 inhibitor Repatha; PhRMA boosts lobbying spending in the second quarter
New rules will require manufacturers to report some indirect payments made to physicians for CME activities.
The agency plans to research extrinsic factors that influence the way a patient perceives a drug.
The agency and community program provider will form a new healthcare marketing company, Relevate Health Group.
Robert Ingram sounds off on drug transparency laws in WSJ op-ed; patients with certain forms of leukemia went into complete remission after taking Amgen's cancer drug; Eli Lilly's future in Alzheimer's disease pinned to new data surfacing this week
Gilead will limit financial assistance to patients to pressure payers; Biogen reports another PML case related to Tecfidera; Valeant buys Egyptian drugmaker
The National Organization for Rare Disorders and the University of Maryland will develop a training program to help caregivers and patients participate in research.
The pharma business needs to take engagement far more seriously than it has in the past. At the same time, there are signs that the industry is finally acting with more urgency and even transparency.
The FDA discusses working with Google to identify unknown drug side effects; Tavenner named chief of insurer lobby group; drugmakers are starting to use cultural experts to better understand patient experience.
The backlash to expensive specialty medications has forced the drug industry to partner up to prove the benefits of their medicines in the real world, according to a PwC analysis.
The restructuring is expected to simplify the drugmaker's organization.
Celgene announces $7.2-billion bid for Receptos; Cytokinetics is using Ice Bucket Challenge donations to test experimental drug; GlaxoSmithKline conducts media review for its consumer health brands
Johnson & Johnson CEO Alex Gorsky said physicians are unlikely to switch the majority of patients to a biosimilar version of Remicade.
Vesey Street Capital Partners acquired Atlanta-based CME provider Imedex.
The FDA approves AstraZeneca's Iressa as a first-line lung-cancer therapy; Mylan and Dr. Reddy's launch generic versions of dementia treatment Namenda; health insurer consolidation may lead to pressure on drug prices
PhRMA and the Epilepsy Foundation said 50-million Americans are affected by disorders such as Alzheimer's disease and multiple sclerosis.
Harvoni is now prescribed more than Sovaldi; healthcare group says new hepatitis-C drugs are cost-effective; Roche antibody shrank tumors in certain bladder-cancer patients
Pharma's efforts to evolve restrictions about off-label marketing move forward.
21st Century Cures legislation passes the House; Novartis's heart-failure drug may launch with "beyond the pill" services; Purdue and GSK are working on using Apple's ResearchKit; the FDA issues warning letter on co-pay card
Click the link below to access the Digital Edition of the July 2015 issue of MM&M, with all text, charts and pictures.
Eli Lilly's lung-cancer antibody, necitumumab, has incremental benefits, according to an FDA advisory panel.
The legislation would allow drugmakers to share information about their products beyond what is included on the FDA-approved label.
Pregnant women taking Prozac or Paxil have higher risks of birth defects; study finds J&J's experimental psoriasis drug works better than Humira; AstraZeneca divests global rights to Entocort
Last year's increase in CME support from manufacturers came after six straight years of declining budgets.
An FDA advisory panel will discuss the fate of Lilly's investigational lung-cancer antibody, necitumumab, which improved overall survival incrementally but also had one late-stage trial halted due to an "imbalanced number of deaths" attributed to blood clots.
The FDA approval this week of a new heart-failure drug is expected to spur interest among cardiologists seeking new ways to keep patients with heart failure out of the hospital.
The agency adds health and wellness offerings to the holding company's existing capabilities.
CDC report finds prescription painkiller abuse contributed to an increase in heroin use; Novartis heart-failure drug gets FDA approval; Isis Pharmaceuticals obtains orphan-drug designation for volanesorsen
An analysis by a state insurance trade group forecast that paying for new HCV treatments could cost taxpayers billions of dollars.
Three panelists from the FDA's advisory panel offered their views on the panel's decision to recommend approval of Sprout Pharmaceuticals' flibanserin
Groups urge disclosure of payments to nurse practitioners and physician assistants; Horizon seeks $3-billion acquisition of Depomed; Sanofi closes $245-million agreement to buy priority-review voucher
The finalists in each of the 32 categories for this year's MM&M Awards are revealed here.
The Boston-based biotech saw its novel cystic-fibrosis drug, Orkambi, receive approval, but it could face an uphill climb in convincing payers to pay for it.
Dr. Stephen Ostroff took over as the FDA's acting commissioner when Dr. Margaret Hamburg stepped down in March.
Vertex's cystic-fibrosis drug scores approval; Bloomberg Business analysis finds competitive product categories attract the most marketing dollars; Allergan makes a deal with developmental medical-device company
Please open the PDF (named Index) below for a complete listing from our July 2015 issue
North American healthcare agencies and the holding companies that own them
Biogen pursues orphan eye-disease treatments; Novo Nordisk will stop selling Tresiba in Germany over price controversy; the switch to Prevnar 13 is expected to lower costs
Digital accounts for more than happiness
An agency with a "no walls" philosophy
Motivation, ability and trigger
Keeping up with the times while integrating into a new family
A veteran Chicago shop has a new parent
Offering clients solutions they didn't even know they needed yet
A smaller agency thinks and acts big
Aligning across healthcare's continuum
A surge follows an acquisition
Independence has its rewards
A new move promotes new energy
Networks and agencies, ranked by 2014 US revenue
An agency with degrees of certainty
Daredevil depth-defying devotion
Real transformation in action
Making a specialty of specialty work
Searching for transformational change
Transparency: right for clients and staff
A sharp focus on managed markets
A rebranded leadership team leads a rebranded agency
Keeping steady amid storms
Realignment leads to rebranding and success (plus flexibility and growth)
An agency running on all cylinders
A young agency transcends its "conflict shop" lineage
The social networking site for doctors also plans to expand to its first Spanish-speaking country next month.
Fusing behavioral science with the art of storytelling
The health insurance industry's trade association, along with other organizations, sent a letter to the FDA arguing that different names could lead to prescriber confusion and medication errors.
Building growth on marketing analytics
A Caroline shop looks to diversify
Coming out ahead after an acquisition
A merger that makes sense
A launch agency keeps new-product role
Being part of something bigger is okay
Pushing the envelope to evolve wisely
Distinguishing itself from its sister firms
Reaching a tipping point is both exciting and rewarding
Guileless enthusiasm speaks volumes
A transitional year paved the way for new openings at this venerable agency
Trustworthiness is a business basic for this longtime Boston agency
Moving beyond dental while steadily pushing into digital
Ice cream? Salons? Klick does it all, and does it well
Being one of the best one-stop shops makes growing all the easier
This digital firm has made the fully realized leap from 2-D to 3-D
Agency business again appears to be up for a healthy cross-section of companies this year. And, according to our annual business barometer of healthcare firms, the new agency is thriving on a diet of mostly digital work on both the HCP and consumer sides. Meanwhile, the increased emphasis on creating memorable content and patient-centered user experiences appears to be a driving force in pharmaceutical clients' marketing strategy. Marc Iskowitz reports
Focusing on a solid set of core skills
A new name but a story long in the making
Digital prowess drives this Kansas City-based agency toward the $100-million mark
As US pharma continued its quest for a Grand Prix at the Lions Health international festival of creativity, MM&M went on location to Cannes, France. Missed our coverage from June? Now, we're giving you an opportunity to catch up on some of what you missed. Download our e-book on the two-day festival, recapping the event, rounding up the best of the speakers, offering perspective and listing all of the winners. Click here to download.
The most recent MM&M Skill Sets Live event surveyed a range of issues relating to one of the hottest promotional spaces in healthcare. Speakers and panelists at the morning-long session, including promotional- and multichannel-minded executives from GSK, Epocrates, Treato and Montefiore Medical Center, weighed in on topics designed to help marketers demystify the challenges associated with non-personal promotion. Click here.